Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
Clinical trial NCT01895361 · COMPLETED
Trial details
- NCT number
- NCT01895361
- Sponsor
- Reprixys Pharmaceutical Corporation
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-07-01
- Primary completion
- 2016-03-01
- Enrollment
- 198
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.